• 1.

    Prymak C, McKee LJ, Goldschmidt MH, et al. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc 1988;193:706712.

    • Search Google Scholar
    • Export Citation
  • 2.

    Spangler WL, Culbertson MR. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985–1989). J Am Vet Med Assoc 1992;200:829834.

    • Search Google Scholar
    • Export Citation
  • 3.

    Oksanen A. Haemagiosarcoma in dogs. J Comp Pathol 1978;88:585595.

  • 4.

    Waller T, Rubarth S. Hemangioendothelioma in domestic animals. Acta Vet Scand 1967;8:234261.

  • 5.

    Ng CY, Mills JN. Clinical and haematological features of haemangiosarcoma in dogs. Aust Vet J 1985;62:14.

  • 6.

    Pearson GR, Head KW. Malignant haemangioendothelioma (angiosarcoma) in the dog. J Small Anim Pract 1976;17:737745.

  • 7.

    Kleine LJ, Zook BC, Munson TO. Primary cardiac hemangiosarcomas in dogs. J Am Vet Med Assoc 1970;157:326337.

  • 8.

    Srebernik N, Appleby EC. Breed prevalence and sites of haemangioma and haemangiosarcoma in dogs. Vet Rec 1991;129:408409.

  • 9.

    Arp LH, Grier RL. Disseminated cutaneous hemangiosarcoma in a young dog. J Am Vet Med Assoc 1984;185:671673.

  • 10.

    Fees DL, Withrow SJ. Canine hemangiosarcoma. Compend Contin Educ Pract Vet 1981;3:10471052.

  • 11.

    Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc 1985;186:5658.

  • 12.

    Martinez SA, Schulman AJ. Hemangiosarcoma of the urinary bladder in a dog. J Am Vet Med Assoc 1988;192:655656.

  • 13.

    Aronsohn M. Cardiac hemangiosarcoma in the dog: a review of 38 cases. J Am Vet Med Assoc 1985;187:922926.

  • 14.

    Dunning D, Monnet E, Orton EC, et al. Analysis of prognostic indicators for dogs with pericardial effusion: 46 cases (1985–1996). J Am Vet Med Assoc 1998;212:12761280.

    • Search Google Scholar
    • Export Citation
  • 15.

    Wykes PM, Rouse GP, Orton EC. Removal of five canine cardiac tumors using a stapling instrument. Vet Surg 1986;15:103106.

  • 16.

    Waters DJ, Caywood DD, Hayden DW, et al. Metastatic pattern in dogs with splenic hemangiosarcoma: clinical implications. J Small Anim Pract 1988;29:805814.

    • Search Google Scholar
    • Export Citation
  • 17.

    Johnson KA, Powers BE, Withrow SJ, et al. Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy. J Vet Intern Med 1989;3:160166.

    • Search Google Scholar
    • Export Citation
  • 18.

    Hirsch VM, Jacobsen J, Mills JH. A retrospective study of canine hemangiosarcoma and its association with acanthocytosis. Can Vet J 1981;22:152155.

    • Search Google Scholar
    • Export Citation
  • 19.

    Frey AJ, Betts CW. A retrospective study of splenectomy in the dog. J Am Anim Hosp Assoc 1977;13:730734.

  • 20.

    Hammer AS, Couto CG. Diagnosing and treating canine hemangiosarcoma. Vet Med (Praha) 1992;87:188192.

  • 21.

    Bingel SA, Brodey RS, Allen HL, et al. Haemangiosarcoma of bone in the dog. J Small Anim Pract 1974;15:303322.

  • 22.

    Culbertson MR Jr Hemangiosarcoma of the canine skin and tongue. Vet Pathol 1982;19:556558.

  • 23.

    Crow SE, Bell TG, Wortman JA. Hematuria associated with renal hemangiosarcoma in a dog. J Am Vet Med Assoc 1980;176:531533.

  • 24.

    White JV, Dunstan RW. Clinical and histopathologic evaluation of canine dermal angiosarcoma: a case report. J Am Anim Hosp Assoc 1984;20:607611.

    • Search Google Scholar
    • Export Citation
  • 25.

    Parchman MB, Crameris FM. Primary vertebral hemangiosarcoma in a dog. J Am Vet Med Assoc 1989;194:7981.

  • 26.

    Ware WA, Hopper DL. Cardiac tumors in dogs: 1982–1995. J Vet Intern Med 1999;13:95103.

  • 27.

    Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370376.

    • Search Google Scholar
    • Export Citation
  • 28.

    Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379384.

  • 29.

    Ward H, Fox LE, Calderwood-Mays MB, et al. Cutaneous hemangiosarcoma in 25 dogs: a retrospective study. J Vet Intern Med 1994;8:345348.

  • 30.

    Hammer AS, Couto CG, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160166.

    • Search Google Scholar
    • Export Citation
  • 31.

    Moore AS, Ogilvie GK. Managing the veterinary cancer patient: a practice manual. Trenton, NJ: Veterinary Learning Systems Co Inc, 1995;367380.

    • Search Google Scholar
    • Export Citation
  • 32.

    Hargis AM, Ihrke PJ, Spangler WL, et al. A retrospective clinicopathologic study of 212 dogs with cutaneous hemangiomas and hemangiosarcomas. Vet Pathol 1992;29:316328.

    • Search Google Scholar
    • Export Citation
  • 33.

    Conroy JD. Canine skin tumors. J Am Anim Hosp Assoc 1983;19:91114.

  • 34.

    MacEwen GE. Miscellaneous tumors; hemangiosarcoma. In: Withrow SJ, MacEwen GE, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;639646.

    • Search Google Scholar
    • Export Citation
  • 35.

    Hargis AM, Lee AC, Thomassen RW. Tumor and tumor-like lesions of the perilimbal conjunctiva in laboratory dogs. J Am Vet Med Assoc 1978;173:11851190.

    • Search Google Scholar
    • Export Citation
  • 36.

    Nikula KJ, Benjamin SA, Angleton GM, et al. Ultraviolet radiation, solar dermatosis, and cutaneous neoplasia in beagle dogs. Radiat Res 1992;129:1118.

    • Search Google Scholar
    • Export Citation
  • 37.

    Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol 2005;29:983996.

    • Search Google Scholar
    • Export Citation
  • 38.

    Bolin DJ, Lukas GM. Low-grade dermal angiosarcoma of the breast following radiotherapy. Am Surg 1996;62:668672.

  • 39.

    Wood CA, Moore AS, Gliatto JM, et al. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991–1993). J Am Anim Hosp Assoc 1998;34:417421.

    • Search Google Scholar
    • Export Citation
  • 40.

    Vail DM. Veterinary co-operative oncology group—common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194213.

    • Search Google Scholar
    • Export Citation

Advertisement

Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001–2006)

Eric J. Bulakowski DVM1, Jeff C. Philibert DVM, DACVIM2, Sheri Siegel DVM, DACVR3, Craig A. Clifford MS, DVM, DACVIM4, Rebecca Risbon VMD, DACVIM5, Kara Zivin PhD6, and Kim L. Cronin DVM, DACVIM7
View More View Less
  • 1 New England Veterinary Oncology Group, Ste C, 180 Bear Hill Rd, Waltham, MA 02454.
  • | 2 New England Veterinary Oncology Group, Ste C, 180 Bear Hill Rd, Waltham, MA 02454.
  • | 3 New England Veterinary Oncology Group, Ste C, 180 Bear Hill Rd, Waltham, MA 02454.
  • | 4 Red Bank Veterinary Hospital, 197 Hance Ave, Tinton Falls, NJ 07724.
  • | 5 Red Bank Veterinary Hospital, 197 Hance Ave, Tinton Falls, NJ 07724.
  • | 6 National Serious Mental Illness Treatment Research and Evaluation Center (SMITREC), Department of Psychiatry and Veteran Affairs, University of Michigan, Ann Arbor, MI 48103.
  • | 7 New England Veterinary Oncology Group, Ste C, 180 Bear Hill Rd, Waltham, MA 02454.

Abstract

Objective—To evaluate outcome associated with subcutaneous and intramuscular hemangiosarcomas treated with adjuvant doxorubicin in dogs.

Design—Retrospective case series.

Animals—21 dogs.

Procedures—Records of dogs with histologically confirmed hemangiosarcoma, no detectable metastasis at initial evaluation, and adequate local tumor control were included. Age, sex, number of treatments, treatment interval, radiation therapy, and concurrent use of cyclophosphamide or deracoxib were evaluated for associations with disease-free interval (DFI) or survival time. Three to 6 cycles of doxorubicin were planned. Disease-free interval was defined as time of definitive surgery to time of local recurrence, metastasis, or both. Survival time was defined as the beginning of the DFI to time of death.

Results—17 tumors were subcutaneous, and 4 were intramuscular. Median age was 9 years. Median weight was 31.1 kg (68.4 lb). Five dogs received adjuvant radiation therapy. Median DFI for subcutaneous tumors was 1,553 days (95% confidence interval [CI], 469 days to not estimable). Median DFI for intramuscular tumors was 265.5 days (95% CI, 123 to 301 days). Median survival time for subcutaneous tumors was 1,189 days (95% CI, 596 days to not estimable). Median survival time for intramuscular tumors was 272.5 days (95% CI, 123 to 355 days). For dogs with subcutaneous tumors, younger age (< 9 years) was associated with longer DFI and survival time. Dogs with subcutaneous tumors that did not receive radiation therapy had longer DFI.

Conclusions and Clinical Relevance—Dogs with subcutaneous hemangiosarcoma had a more favorable outcome, compared with dogs with intramuscular hemangiosarcoma, when treated with adequate local control and adjuvant doxorubicin.

Abstract

Objective—To evaluate outcome associated with subcutaneous and intramuscular hemangiosarcomas treated with adjuvant doxorubicin in dogs.

Design—Retrospective case series.

Animals—21 dogs.

Procedures—Records of dogs with histologically confirmed hemangiosarcoma, no detectable metastasis at initial evaluation, and adequate local tumor control were included. Age, sex, number of treatments, treatment interval, radiation therapy, and concurrent use of cyclophosphamide or deracoxib were evaluated for associations with disease-free interval (DFI) or survival time. Three to 6 cycles of doxorubicin were planned. Disease-free interval was defined as time of definitive surgery to time of local recurrence, metastasis, or both. Survival time was defined as the beginning of the DFI to time of death.

Results—17 tumors were subcutaneous, and 4 were intramuscular. Median age was 9 years. Median weight was 31.1 kg (68.4 lb). Five dogs received adjuvant radiation therapy. Median DFI for subcutaneous tumors was 1,553 days (95% confidence interval [CI], 469 days to not estimable). Median DFI for intramuscular tumors was 265.5 days (95% CI, 123 to 301 days). Median survival time for subcutaneous tumors was 1,189 days (95% CI, 596 days to not estimable). Median survival time for intramuscular tumors was 272.5 days (95% CI, 123 to 355 days). For dogs with subcutaneous tumors, younger age (< 9 years) was associated with longer DFI and survival time. Dogs with subcutaneous tumors that did not receive radiation therapy had longer DFI.

Conclusions and Clinical Relevance—Dogs with subcutaneous hemangiosarcoma had a more favorable outcome, compared with dogs with intramuscular hemangiosarcoma, when treated with adequate local control and adjuvant doxorubicin.

Contributor Notes

Dr. Bulakowski's present address is Michigan Veterinary Specialists, 3412 E Walton Blvd, Auburn Hills, MI 48326.

Supported by an educational grant from Novartis Animal Health US Incorporated.

Presented at the 26th Annual Conference of the Veterinary Cancer Society, Callaway Gardens, Pine Mountain, Ga, October 2006.

The authors thank Steven V. Radecki for statistical analyses.

Address correspondence to Dr. Bulakowski.